Condition: Generalized Myasthenia Gravis (gMG) · Sponsor: Daishi Tian
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.
This description comes directly from the study's public registry record.
Chuan Qin Sub-I · 13886052650 · chuanqin@tjh.tjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07058298